ABBOTT PARK, Ill., Sept. 22, 2021 — Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Epic™ Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. These next-generation devices build off Abbott's Epic surgical valve platform – which has a decades-long history of safety and strong clinical outcomes – and include innovations that make implantation of the valve and future cardiac interventions easier.